Prostatic Cancer: Advances in Diagnosis

  • L. Denis
  • A. Van Steirteghem
Part of the NATO Advanced Science Institutes Series book series (NSSA, volume 53)


Prostatic cancer constitutes one of the most commonly diagnosed cancers in older males (1). The accumulated information concerning this disease is enormous but we are still unable to diagnose the disease in the early stages, to assess the extent of disease in a non invasive way or to select treatment according to the lethal potential of the tumor. This paper brings data together that have or seem to have value in establishing answers to these three questions. Any of these problems, if answered, would represent a true advance in diagnosis. Physical examination, histological confirmation by biopsy, medical imaging techniques and prostatic tumor markers have been selected for presentation.


Prostatic Cancer Acid Phosphatase Transrectal Ultrasonography Prostatic Acid Phosphatase Early Prostatic Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C. Bouffioux, Le Cancer de la Prostate, Acta Urol. Belg. 47:190 (1979).Google Scholar
  2. 2.
    H.J. Jewett, Significance of the palpable prostatic nodule, JAMA 160:838 (1956).CrossRefGoogle Scholar
  3. 3.
    G. Guinan, I. Bush, V. Ray, R. Vieth, R. Rao, and R. Bhatti, The accuracy of the rectal examination in the diagnosis of prostate carcinoma, New. Engl. J. Med. 303:499 (1980).PubMedCrossRefGoogle Scholar
  4. 4.
    W.J. Catalona, Yield from routine prostatic needle biopsy in patients more than 50 years old referred for urologic evaluations: A preliminary report, J. Urol. 124:844 (1980).PubMedGoogle Scholar
  5. 5.
    D.P. Byar, F.K. Mostofi, and VACURG, Carcinoma of the prostate. Prognostic evaluation of certain pathological features in 208 radical prostatectomies, Cancer 30:5 (1972).PubMedCrossRefGoogle Scholar
  6. 6.
    M.R.G. Robinson, Personal Communication.Google Scholar
  7. 7.
    P.B. Hudson, A.L. Finkle, A.J. Hopkens, E.E. Sproul, and A.P. Stout, Prostatic cancer XI early prostatic cancer diagnosed by arbitrary open perineal biopsy among 300 unselected patients, Cancer 7:690 (1954).PubMedCrossRefGoogle Scholar
  8. 8.
    D.P. Byar and VACURG, Survival of patients with incidentally found microscopic cancer of the prostate. Results of a clinical trial of conservative treatment, J. Urol. 108:908 (1972).PubMedGoogle Scholar
  9. 9.
    A.C. Broders, Grading of Carcinoma, Minnesota Med. 8:726 (1925).Google Scholar
  10. 10.
    F.K. Mostofi, Problems of grading carcinoma of the prostate, Semin. Oncol. 3:161 (1976).PubMedGoogle Scholar
  11. 11.
    D.F. Gleason, G.T. Mellinger, and VACURG, Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging, J. Urol. 111:58 (1974).PubMedGoogle Scholar
  12. 12.
    D.F. Paulson, P.V. Piserchia, and W. Gardner, Predictors of lymphatic spread in prostatic adeno-carcinoma. Uro-oncology Research Group study, J. Urol. 123:697 (1980).PubMedGoogle Scholar
  13. 13.
    J.F. Gaeta, J.E. Asurwatham, G. Miller, and G.P. Murphy, Histologic grading of primary prostatic cancer. A new approach to an old problem, J. Urol. 123:689 (1980).PubMedGoogle Scholar
  14. 14.
    L. Denis, Clinical cancer of prostate. Influence of tumor stage and grade on five year survival, Acta Urol. Belg. 40:126 (1972).PubMedGoogle Scholar
  15. 15.
    P.J.B. Carstens, Perineural glands in normal and hyperplastic prostates, J. Urol. 123:686 (1980).PubMedGoogle Scholar
  16. 16.
    N. O’Donoghue and R. Pugh, Early diagnosis of prostatic carcinoma: the role of trans-urethral resection, Brit. J. Urol. 116:759 (1976).Google Scholar
  17. 17.
    W.J. Catalona and M. Menon, New screening and diagnostic tests for prostate cancer and immunologie assessment, Suppl. to Urology 17:61 (1981).Google Scholar
  18. 18.
    J.M. Barry, A. Goldstein, and M. Hubbard, Human leucocyte A and B antigens in patients with prostatic adenocarcinoma, J. Urol. 124:847 (1980).PubMedGoogle Scholar
  19. 19.
    G.R. Prout Jr., P. Griffin, J.J. Daly, and W.U. Shipley, Nodal involvement as prognostic indicator in prostatic carcinoma, Suppl, to Urology 17:72 (1981).Google Scholar
  20. 20.
    C.B. Brendler, L.K. Cleeve, E. Anderson, and D.F. Paulson, Staging pelvic lymphadenectomy for carcinoma of the prostate: risk versus benefit, J. Urol. 124:849 (1980).PubMedGoogle Scholar
  21. 21.
    L. Denis, L. Appel, J. Broos, and G. Declercq, Evaluation of prostatic cancer by transrectal ultrasonography and CT scan, Acta Urol. Belg. 48:71 (1980).PubMedGoogle Scholar
  22. 22.
    M.I. Resnick, Non invasive techniques in evaluating patients with carcinoma of the prostate, Suppl. to Urology, 17:25 (1981).Google Scholar
  23. 23.
    J. Pradel, J.M. Duclos, M. Charton, and J.M. Brussel, La tomodensitometrie dans le bilan d’extension des cancers prostatiques, in: “Sem. D’Uro-Nephrologie,” R. Kuss and M. Legrain, eds., Masson, Paris (1981), p.31.Google Scholar
  24. 24.
    G. Declercq, L. Denis, J. Broos, and L. Appel, Evaluation of lower urinary tract by computed tomography and transrectal ultrasonography, Comp. Tom. In Press.Google Scholar
  25. 25.
    H. Watanabe, S.H. Holmes, H.J. Holm, and B.B. Goldberg, “Diagnostic Ultrasound in Urology and Nephrology,” Ingaku Shion Ltd., Tokyo (1981).Google Scholar
  26. 26.
    H.H. Holm and J. Gammelgaard, Ultrasonically guided precise needle placement in the prostate and the seminal vesicles, J. Urol. 125:385 (1981).PubMedGoogle Scholar
  27. 27.
    H. Watanabe, T. Mishina, and H. Ohe, Mass screening of prostatic diseases, in: “Prostatic Carcinoma and Biology and Diagnosis,” E.S.E. Hafez and E. Spring Mills, Martinus Nyhoff, The Hague (1981), p.71.CrossRefGoogle Scholar
  28. 28.
    E.B. Gutman, E.E. Sproul, and A.B. Gutman, Increased phosphatase activity of bone at site of osteoplastic metastases secondary to carcinoma of prostate gland, Am. J. Cancer 28:485 (1936).Google Scholar
  29. 29.
    A.V. Roy, M.E. Brouwer, and J.E. Hayden, Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostate in serum, Clin. Chem. 17:1093 (1971).PubMedGoogle Scholar
  30. 30.
    C.Y. Li, R.A. Chuda, W.K.W. Lam, and L.T. Yam, Acid phosphatases in human plasma, J. Lab. Clin. Med. 82:446 (1973).PubMedGoogle Scholar
  31. 31.
    W.H. Fishman and F. Lerner, A method for estimating serum acid phosphatase of prostatic origin, J. Biol. Chem. 200:89 (1953).PubMedGoogle Scholar
  32. 32.
    J.F. Cooper and A.G. Foti, A radioimmunoassay for prostatic acid phosphatase. I. Methodology and range of normal male serum values, Invest. Urol. 12:98 (1974).Google Scholar
  33. 33.
    J.F. Cooper and A.G. Foti, A radioimmunoassay for prostatic acid phosphatase, Nat. Can. Inst. Monograph 49:235 (1978).Google Scholar
  34. 34.
    J.F. Cooper, A.G. Foti, and P.W. Shank, Radioimmunochemical measurement of bone marrow prostatic acid phosphatase, J. Urol. 119:388 (1978).PubMedGoogle Scholar
  35. 35.
    P. Vihko, E. Sajanti, O. Jänne, L. Peltonen, and R. Vihko, Serum prostate-specific acid phosphatase: development and validation of a specific radioimmunoassay, Clin. Chem. 24:1915 (1978).PubMedGoogle Scholar
  36. 36.
    T.M. Chu, M.C. Wang, R. Kajdasz, E.A. Barnard, P. Kucil, and G.P. Murphy, Prostate-specific acid phosphohydrolase in the diagnosis of prostate cancer, Proc. Am. Assoc. Cancer Res. 17:191 (1976).Google Scholar
  37. 37.
    T.M. Chu, Serum acid phosphohydrolase (phosphatase) and ribonuclease in diagnosis of prostatic cancer, Antibiotics Chemotherapy 22:98 (1978).Google Scholar
  38. 38.
    C.L. Lee, M.C. Wang, G.P. Murphy, and T.M. Chu, A solid phase fluorescent immunoassay for human prostatic acid phosphatase, Cancer Res. 38:2871 (1978).PubMedGoogle Scholar
  39. 39.
    C.L. Lee, C.S. Killian, G.P. Murphy, and T.M. Chu, A solid-phase immunoadsorbant assay for serum prostatic acid phosphatase, Clin. Chim. Acta 101:209 (1980).PubMedCrossRefGoogle Scholar
  40. 40.
    R.S. Galen and S.R. Gambino,’Beyond Normality: The Predictive Value and Efficiency of Medical Diagnosis,” Wiley, New York (1975).Google Scholar
  41. 41.
    J.C Griffiths, Prostate-specific acid phosphatase: re-evaluation of radioimmunoassay in diagnosing prostatic disease, Clin. Chem. 26:433 (1980).PubMedGoogle Scholar
  42. 42.
    A.G. Foti, J.F. Cooper, H. Herschman, and R.R. Malvaez, Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase, New Engl. J. Med. 297:1357 (1977).PubMedCrossRefGoogle Scholar
  43. 43.
    D.M. Goldberg and G. Ellis, An assessment of serum acid and alkaline phosphatase determination in prostatic cancer with a clinical validation of an acid phosphatase assay utilizing adenosine 3′-monophosphatate as substrate, J. Clin. Pathol. 27:140 (1974).PubMedCrossRefGoogle Scholar
  44. 44.
    A.W. Bruce, D.E. Mahan, A. Morales, A.F. Clark, and W.D. Belville, An objective look at acid phosphatase determinations. A comparison of biochemical and immunological methods, Brit. J. Urol 51:213 (1979).PubMedCrossRefGoogle Scholar
  45. 45.
    A. Wajsman, T.M. Chu, J. Saroff, N. Slack, and G.P. Murphy, Two new, direct and specific methods of acid phosphatase determination, National field Trial. Urology 13:8 (1979).PubMedCrossRefGoogle Scholar
  46. 46.
    D.E. Mahan and B.P. Doctor, A radioimmune assay for human prostatic acid phosphatase-levels in prostatic disease, Clin. Biochem. 12:10 (1979).PubMedCrossRefGoogle Scholar
  47. 47.
    A.W. Bruce, D.E. Mahan, L.D. Sullivan, and L. Goldenberg, The significance of prostatic acid phosphatase in adenocarcinoma of the prostate, J. Urol. 125:357 (1981).PubMedGoogle Scholar
  48. 48.
    G.R. Quinones, T.J. Rohnef, J.R. Drago, and L.M. Demers, Will prostatic acid phosphatase determination by radioimmunoassay increase the diagnosis of early prostatic cancer? J. Urol. 125:361 (1981).PubMedGoogle Scholar
  49. 49.
    M.H. Zweig, A.C. Steirteghem, and A.N. Schechter, Radioimmunoassay of creatine kinase isoenzymes in human serum, Isoenzyme BB, Clin. Chem. 24:422 (1978).PubMedGoogle Scholar
  50. 50.
    P.D. Feld and D.L. Witte, Presence of creatine kinase BB iso-enzymes in some patients with prostatic carcinoma, Clin. Chem. 23:1930 (1977).PubMedGoogle Scholar
  51. 51.
    R.D. Feld, A.C. Van Steirteghem, M. H. Zweig, G.W. Weimar, A.S. Narayana, and D.L. Witte, The presence of creatine kinase BB isoenzyme in patients with prostatic cancer, Clin. Chim. Acta 100:267 (1980).PubMedCrossRefGoogle Scholar
  52. 52.
    L.M. Silverman, G.B. Demer, M.H. Zweig, A.C. Van Steirteghem, and Z.A. Tökés, Creatine kinase BB: a new tumor associated marker, Clin. Chem. 25:1432 (1979).PubMedGoogle Scholar
  53. 53.
    M.H. Zweig and A.C. Van Steirteghem, Serum creatine kinase BB (RIA) as a tumor marker: Studies in various cancers and a comparison to prostatic acid phosphatase, J. Nat. Canc. Inst. In Press.Google Scholar
  54. 54.
    R.Y. Kirdani, J.P. Karr, G.P. Murphy, and A.A. Sandberg, Clinical markers in prostatic cancer, in: “Prostatic Carcinoma — Biology and Diagnosis,” E.S.E. Hafez and Spring — Mills, eds, Martinus Nyhoff, The Hague (1981), p.79.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1983

Authors and Affiliations

  • L. Denis
    • 1
  • A. Van Steirteghem
    • 1
  1. 1.Academic HospitalFree University of BrusselsA.Z. Middelheim (Antwerp)Belgium

Personalised recommendations